V A Levin

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. ncbi Phase III randomized study of postradiotherapy chemotherapy with alpha-difluoromethylornithine-procarbazine, N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosurea, vincristine (DFMO-PCV) versus PCV for glioblastoma multiforme
    V A Levin
    Department of Neuro Oncology, University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Clin Cancer Res 6:3878-84. 2000
  2. ncbi Combination chemotherapy with 13-cis-retinoic acid and celecoxib in the treatment of glioblastoma multiforme
    V A Levin
    Neuro Oncology Unit 431, Department of Neuro Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77230 1402, USA
    J Neurooncol 78:85-90. 2006
  3. ncbi Randomized, double-blind, placebo-controlled trial of marimastat in glioblastoma multiforme patients following surgery and irradiation
    Victor A Levin
    Department of Neuro Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Neurooncol 78:295-302. 2006
  4. ncbi Different changes in protein and phosphoprotein levels result from serum starvation of high-grade glioma and adenocarcinoma cell lines
    Victor A Levin
    Departments of Neuro Oncology, Bioinformatics and Computational Biology, and Blood and Marrow Transplantation, Section of Molecular Hematology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77230, USA
    J Proteome Res 9:179-91. 2010
  5. ncbi Phase III randomized study of postradiotherapy chemotherapy with combination alpha-difluoromethylornithine-PCV versus PCV for anaplastic gliomas
    Victor A Levin
    Department of Neuro Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Clin Cancer Res 9:981-90. 2003
  6. ncbi Relationship between ornithine decarboxylase levels in anaplastic gliomas and progression-free survival in patients treated with DFMO-PCV chemotherapy
    Victor A Levin
    Department of Neuro Oncology and M D Anderson Clinical Oncology Program, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Int J Cancer 121:2279-83. 2007
  7. ncbi Impact of phase II trials with progression-free survival as end-points on survival-based phase III studies in patients with anaplastic gliomas
    Victor A Levin
    Department of Neuro Oncology, Unit 431, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    BMC Cancer 7:106. 2007
  8. ncbi Phase II study of accelerated fractionation radiation therapy with carboplatin followed by PCV chemotherapy for the treatment of anaplastic gliomas
    V A Levin
    Department of Neuro Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 53:58-66. 2002
  9. ncbi Tissue-based assay for ornithine decarboxylase to identify patients likely to respond to difluoromethylornithine
    Victor A Levin
    Dept of Neuro Oncology, Unit 431, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030 4009, USA
    J Histochem Cytochem 52:1467-74. 2004
  10. ncbi A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse
    W K Yung
    Department of Neuro Oncology, UTMD Anderson Cancer Center, Box 100, 1515 Holcombe Boulevard, Houston, Texas, 77030, USA
    Br J Cancer 83:588-93. 2000

Detail Information

Publications47

  1. ncbi Phase III randomized study of postradiotherapy chemotherapy with alpha-difluoromethylornithine-procarbazine, N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosurea, vincristine (DFMO-PCV) versus PCV for glioblastoma multiforme
    V A Levin
    Department of Neuro Oncology, University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Clin Cancer Res 6:3878-84. 2000
    ..PCV is still ongoing and hopefully will yield more encouraging results...
  2. ncbi Combination chemotherapy with 13-cis-retinoic acid and celecoxib in the treatment of glioblastoma multiforme
    V A Levin
    Neuro Oncology Unit 431, Department of Neuro Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77230 1402, USA
    J Neurooncol 78:85-90. 2006
    ..From this, we concluded that the animal studies generally predicted that the two agents would have only a modest effect alone and no additive effect when given in combination to patients...
  3. ncbi Randomized, double-blind, placebo-controlled trial of marimastat in glioblastoma multiforme patients following surgery and irradiation
    Victor A Levin
    Department of Neuro Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Neurooncol 78:295-302. 2006
    ..Because raised matrix metalloprotease (MMP) levels are associated with glioma invasion and angiogenesis, we tested the efficacy of marimastat (MT) an orally active drug that can reduce MMP levels, in patients with gliomas...
  4. ncbi Different changes in protein and phosphoprotein levels result from serum starvation of high-grade glioma and adenocarcinoma cell lines
    Victor A Levin
    Departments of Neuro Oncology, Bioinformatics and Computational Biology, and Blood and Marrow Transplantation, Section of Molecular Hematology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77230, USA
    J Proteome Res 9:179-91. 2010
    ..Contrawise, gliomas become resistant to apoptosis after 24 h of serum starvation and upregulate transcription activators and polyamines more so than adenocarciomas...
  5. ncbi Phase III randomized study of postradiotherapy chemotherapy with combination alpha-difluoromethylornithine-PCV versus PCV for anaplastic gliomas
    Victor A Levin
    Department of Neuro Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Clin Cancer Res 9:981-90. 2003
    ....
  6. ncbi Relationship between ornithine decarboxylase levels in anaplastic gliomas and progression-free survival in patients treated with DFMO-PCV chemotherapy
    Victor A Levin
    Department of Neuro Oncology and M D Anderson Clinical Oncology Program, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Int J Cancer 121:2279-83. 2007
    ..3 nmol/30 min/mug protein. This study shows that Ab-ODC-Alexa 647 fluorescence intensity can be used as a surrogate marker of ODC biochemical activity in AGs and can predict PFS to DFMO-based chemotherapy...
  7. ncbi Impact of phase II trials with progression-free survival as end-points on survival-based phase III studies in patients with anaplastic gliomas
    Victor A Levin
    Department of Neuro Oncology, Unit 431, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    BMC Cancer 7:106. 2007
    ..To assess progression-free survival (PFS) as the appropriate end-point for phase II trials for anaplastic gliomas (AGs) and to determine the impact of PFS on survival-based phase III trials...
  8. ncbi Phase II study of accelerated fractionation radiation therapy with carboplatin followed by PCV chemotherapy for the treatment of anaplastic gliomas
    V A Levin
    Department of Neuro Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 53:58-66. 2002
    ..To conduct a Phase II one-arm study to evaluate the long-term efficacy and safety of accelerated fractionated radiotherapy combined with i.v. carboplatin for patients with previously untreated anaplastic gliomas...
  9. ncbi Tissue-based assay for ornithine decarboxylase to identify patients likely to respond to difluoromethylornithine
    Victor A Levin
    Dept of Neuro Oncology, Unit 431, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030 4009, USA
    J Histochem Cytochem 52:1467-74. 2004
    ....
  10. ncbi A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse
    W K Yung
    Department of Neuro Oncology, UTMD Anderson Cancer Center, Box 100, 1515 Holcombe Boulevard, Houston, Texas, 77030, USA
    Br J Cancer 83:588-93. 2000
    ..44% for PCB patients (P = 0.019). Freedom from disease progression was associated with maintenance of HRQL, regardless of treatment received. TMZ had an acceptable safety profile; most adverse events were mild or moderate in severity...
  11. ncbi TPDC-FuHu chemotherapy for the treatment of recurrent metastatic brain tumors
    S E Kaba
    Department of Neuro Oncology and Biomathematics, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    J Clin Oncol 15:1063-70. 1997
    ..To evaluate a combination of thioguanine, procarbazine, dibromodulcitol, CCNU (CCNU), fluorouracil, and hydroxyurea (TPDC-FuHu), designed to improve the efficacy of CCNU, in the treatment of recurrent metastatic brain tumors...
  12. ncbi The opioid mechanism of interferon-alpha action
    B T Ho
    Department of Neuro Oncology, University of Texas M D Anderson Cancer Center, Houston 77030
    Anticancer Drugs 5:90-4. 1994
    ..d-Amphetamine (0.8 mg/kg) was shown to potentiate both EKC (0.1 mg/kg) and IFN-alpha (1 x 10(6) U/kg). The present study confirms our previously proposed opioid-mediated dopaminergic mechanism of IFN-alpha...
  13. ncbi Two phase II trials of temozolomide with interferon-alpha2b (pegylated and non-pegylated) in patients with recurrent glioblastoma multiforme
    M D Groves
    Department of Neuro Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Br J Cancer 101:615-20. 2009
    ....
  14. ncbi Gamma-radiation sensitivity and risk of glioma
    M L Bondy
    Department of Epidemiology, The University of Texas M D Anderson Cancer Center, Houston, USA
    J Natl Cancer Inst 93:1553-7. 2001
    ....
  15. ncbi Phase II study of 6-thioguanine, procarbazine, dibromodulcitol, lomustine, and vincristine chemotherapy with radiotherapy for treating malignant glioma in children
    V A Levin
    Brain Tumor Center and the Department of Neuro Oncology, Houston, TX 77030, USA
    Neuro Oncol 2:22-8. 2000
    ..The combination of TPDCV chemotherapy and radiation therapy for anaplastic ependymomas appears to be active and at least as good as published reports using radiation therapy alone...
  16. ncbi Cognitive function as a predictor of survival in patients with recurrent malignant glioma
    C A Meyers
    Departments of Neuro Oncology and Biomathematics, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 18:646-50. 2000
    ..To determine the contribution of cognitive function in predicting the survival of patients with recurrent malignant brain tumors...
  17. ncbi Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme
    Morris D Groves
    Department of Neuro-Oncology, University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 20:1383-8. 2002
    ..This drug combination met phase II study criteria; further study in recurrent patients with GBM might be warranted. Further study of therapy-induced joint pain is necessary...
  18. ncbi Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group
    W K Yung
    University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 17:2762-71. 1999
    ..To determine the antitumor efficacy and safety profile of temozolomide in patients with malignant astrocytoma at first relapse...
  19. ncbi Reduced expression of mismatch repair genes measured by multiplex reverse transcription-polymerase chain reaction in human gliomas
    Q Wei
    Department of Epidemiology, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Cancer Res 57:1673-7. 1997
    ..These data suggest that reduced expression of MMR genes is frequent in human gliomas and that aberrant expression of more than one MMR gene may be associated with increased risk of second primary malignancies in glioma patients...
  20. ncbi 13-cis-retinoic acid in the treatment of recurrent glioblastoma multiforme
    Siew-Ju See
    Department of Neuro-Oncology, University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA
    Neuro Oncol 6:253-8. 2004
    ..This data supports the use of cRA in such patients, but its further evaluation in larger, prospective, controlled studies with or without other noncytotoxic and cytotoxic agents may be warranted...
  21. ncbi Fenretinide activates caspases and induces apoptosis in gliomas
    V K Puduvalli
    Department of Neuro Oncology, The University of Texas, M D Anderson Cancer Center, Houston 77030, USA
    Clin Cancer Res 5:2230-5. 1999
    ..The favorable side effect profile seen in previous clinical studies and the in vitro activity against gliomas demonstrated in this study suggest that fenretinide could be a promising therapeutic agent against gliomas...
  22. ncbi Glutathione S-transferase polymorphisms and survival in primary malignant glioma
    M Fatih Okcu
    Department of Pediatrics, Baylor College of Medicine, Houston, Texas, USA
    Clin Cancer Res 10:2618-25. 2004
    ..The purpose of this research was to investigate the relationship between glutathione S-transferase (GST) polymorphisms and survival, and chemotherapy-related toxicity in 278 glioma patients...
  23. ncbi Methylphenidate therapy improves cognition, mood, and function of brain tumor patients
    C A Meyers
    Department of Neuro Oncology, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    J Clin Oncol 16:2522-7. 1998
    ..We sought to determine whether methylphenidate treatment would improve these patients' neurobehavioral functioning despite their expected neurologic deterioration...
  24. ncbi Malignant gliomas: MR imaging spectrum of radiation therapy- and chemotherapy-induced necrosis of the brain after treatment
    A J Kumar
    Division of Diagnostic Imaging, University of Texas M D Anderson Cancer Center, Box 57, Houston, TX 77030, USA
    Radiology 217:377-84. 2000
    ..To describe both the common and less frequently encountered magnetic resonance (MR) imaging features of radiation therapy- and chemotherapy-induced brain injury, with particular emphasis on radiation necrosis...
  25. ncbi Phase II trial of temozolomide plus marimastat for recurrent anaplastic gliomas: a relationship among efficacy, joint toxicity and anticonvulsant status
    Morris D Groves
    Department of Neuro Oncology, Unit 431, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Neurooncol 80:83-90. 2006
    ....
  26. ncbi Long-term anti-inflammatory and antihistamine medication use and adult glioma risk
    Michael E Scheurer
    Department of Epidemiology, University of Texas MD Anderson Cancer Center, PO Box 301439, Houston, TX 77230 1439, USA
    Cancer Epidemiol Biomarkers Prev 17:1277-81. 2008
    ..Our results lend additional support for an important but unknown link between malignant brain tumors and immune mediators...
  27. ncbi Phase II study of fenretinide (NSC 374551) in adults with recurrent malignant gliomas: A North American Brain Tumor Consortium study
    Vinay K Puduvalli
    Department of Neuro Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 431, Houston TX 77030, USA
    J Clin Oncol 22:4282-9. 2004
    ..Fenretinide induces apoptosis in malignant gliomas in vitro. This two-stage phase II trial was conducted to determine the efficacy of fenretinide in adults with recurrent malignant gliomas...
  28. ncbi Phase II trial of irinotecan and thalidomide in adults with recurrent glioblastoma multiforme
    Vinay K Puduvalli
    Department of Neuro Oncology, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Neuro Oncol 10:216-22. 2008
    ..The results also provide support for similar strategies using combination therapies with newer targeted antiangiogenic agents to generate effective therapies against malignant gliomas...
  29. ncbi Posterior fossa decompression for life-threatening tonsillar herniation in patients with gliomatosis cerebri: report of three cases
    Jeffrey S Weinberg
    Department of Neurosurgery, Brain Tumor Center, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Neurosurgery 52:216-23; discussion 223. 2003
    ..Early recognition of this potentially life-threatening complication allowed us to recommend prompt surgical intervention...
  30. ncbi Hypofractionated radiotherapy for elderly or younger low-performance status glioblastoma patients: outcome and prognostic factors
    Eric L Chang
    Division of Radiation Oncology, Brain Tumor Center, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 56:519-28. 2003
    ..To evaluate the outcome for elderly or younger poor prognosis glioblastoma patients treated with hypofractionated radiotherapy (HypoRT)...
  31. ncbi Anaplastic oligodendrogliomas: prognostic factors for tumor recurrence and survival
    Vinay K Puduvalli
    University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Oncology 65:259-66. 2003
    ..In this multicenter retrospective study, we analyzed the clinical characteristics of patients with AO to identify prognostic factors that influence time to progression (TTP) and survival...
  32. ncbi Stereotactic injection of DTI-015 into recurrent malignant gliomas: phase I/II trial
    Samuel J Hassenbusch
    Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Neoplasia 5:9-16. 2003
    ..5 weeks. The results suggest that DTI-015 administered at </=MTD is well tolerated and active in patients with inoperable recurrent GBM...
  33. ncbi Risk assessment for developing gliomas: a comparison of two cytogenetic approaches
    R El-Zein
    Department of Epidemiology, The University of Texas, M.D. Anderson Cancer Center, Box 189, Houston, TX 77030, USA
    Mutat Res 490:35-44. 2001
    ..The results indicate that using the multicolor FISH assay for detection of CIN in peripheral blood lymphocytes in glioma patients is a more useful marker for risk assessment...
  34. ncbi A new preclinical 3-dimensional agarose colony formation assay
    Yoshinori Kajiwara
    Department of Neuro Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77230 1402, USA
    Technol Cancer Res Treat 7:329-34. 2008
    ..In conclusion, the GelCount method that we describe is more quantitative than traditional colony assays and allows precise study of drug effects with respect to both dose and time of exposure using fewer culture plates...
  35. ncbi Basis and importance of Src as a target in cancer
    Victor A Levin
    Department of Neuro-Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, USA
    Cancer Treat Res 119:89-119. 2004
  36. ncbi Polymorphisms of DNA repair genes and risk of glioma
    Li E Wang
    Department of Epidemiology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Res 64:5560-3. 2004
    ..13-2.93). These results suggest that the T allele may be a risk allele, and this XRCC7 polymorphism may be a marker for the susceptibility to glioma. Larger studies are needed to confirm our findings and unravel the underlying mechanisms...
  37. ncbi Neurochemical basis of interleukin 2-modified discrimination behaviour
    B T Ho
    Department of Neuro Oncology, University of Texas, M D Anderson Cancer Center, Houston 77030
    Cytokine 6:365-7. 1994
    ..Data from the present study show that IL-2 exerts the same neurochemical action as that previously observed with IFN-alpha for both d-amphetamine and EKC discrimination in rats...
  38. ncbi Are gliomas preventable?
    Victor A Levin
    Neuro Oncology Unit 431, University of Texas, M D Anderson Cancer Center, Houston 77230 1402, USA
    Recent Results Cancer Res 174:205-15. 2007
    ..Obviously, for the latter to be achieved, we must also be able to diagnose and treat low-grade gliomas earlier...
  39. ncbi Toward better early-phase brain tumor clinical trials: a reappraisal of current methods and proposals for future strategies
    Frederick F Lang
    Department of Neurosurgery, The Brain Tumor Center, The University of Texas MD Anderson Cancer Center, Houston, TX 77005-4009, USA
    Neuro Oncol 4:268-77. 2002
    ..Specifically, the authors recommend brain-applicable phase I and II clinical trial strategies that take advantage of the targeted nature of new agents to maximize information about their efficacy, toxicity, and molecular effects...
  40. ncbi Melding a New 3-Dimensional Agarose Colony Assay with the E(max) Model to Determine the Effects of Drug Combinations on Cancer Cells
    Yoshinori Kajiwara
    Department of Neuro Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77230 1402, USA
    Technol Cancer Res Treat 8:163-76. 2009
    ....
  41. ncbi Advances in gene therapy and immunotherapy for brain tumors
    Yvonne Kew
    Department of Neuro-Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, 77030, USA
    Curr Opin Neurol 16:665-70. 2003
    ....
  42. ncbi Differential expression of two types of the neurofibromatosis type 1 (NF1) gene transcripts related to neuronal differentiation
    T Nishi
    Department of Neuro Oncology, University of Texas M D Anderson Cancer Center, Houston 77030
    Oncogene 6:1555-9. 1991
    ....
  43. ncbi Effect of bevacizumab on radiation necrosis of the brain
    Javier Gonzalez
    Department of Neuro Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77230 1402, USA
    Int J Radiat Oncol Biol Phys 67:323-6. 2007
    ..Because blocking vascular endothelial growth factor (VEGF) from reaching leaky capillaries is a logical strategy for the treatment of radiation necrosis, we reasoned that bevacizumab might be an effective treatment of radiation necrosis...
  44. ncbi Chemotherapy as first line treatment for oligodendroglioma
    Athanassios P Kyritsis
    J Neurooncol 86:361-2. 2008
  45. ncbi Optimizing radiotherapy schedules for elderly glioblastoma multiforme patients
    James W Clarke
    Department of Radiation Medicine, Arthur G James Cancer Hospital, The Ohio State University Medical Center, 300 West 10th Avenue, Ste 083A, Columbus, OH 43210, USA
    Expert Rev Anticancer Ther 8:733-41. 2008
    ..This review aims to evaluate the current state of knowledge on alternative radiotherapy schedules for elderly and poor-prognosis patients with glioblastoma...
  46. ncbi 2-Methoxyestradiol interferes with NF kappa B transcriptional activity in primitive neuroectodermal brain tumors: implications for management
    Addanki P Kumar
    Center for Cancer Causation and Prevention, AMC Cancer Research Center and University of Colorado Comprehensive Cancer Center, Denver, CO 80214, USA
    Carcinogenesis 24:209-16. 2003
    ..In addition, as 2-ME inhibits growth predominantly through G(2)/M block, it may enhance the effectiveness of radiation therapy...
  47. ncbi Formation of DNA adducts and tumor growth delay following intratumoral administration of DTI-015
    William J Bodell
    Laboratory of Molecular Therapeutics, Department of Neurological Surgery, Brain Tumor Research Center, University of California, San Francisco, CA 94143 0555, USA
    J Neurooncol 62:251-8. 2003
    ..These studies demonstrate that IT administration of DTI-015 produces high levels of DNA adducts in the tumor which correspond to a significant increase in tumor growth delay compared to the same dose of BCNU administered systemically...